Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Brain Pathol. Author manuscript; available in PMC 2011 May 1.
Published in final edited form as:
PMCID: PMC2881485

Biomarkers for Cognitive Impairment in Parkinson Disease


Cognitive impairment, including dementia, is commonly seen in those afflicted with Parkinson disease (PD), particularly at advanced disease stages. Pathologically, PD with dementia (PD-D) is most often associated with the presence of cortical Lewy bodies, as is the closely related dementia with Lewy bodies (DLB). Both PD-D and DLB are also frequently complicated by the presence of neurofibrillary tangles and amyloid plaques, features most often attributed to Alzheimer disease. Biomarkers are urgently needed to differentiate among these disease processes and predict dementia in PD as well as monitor responses of patients to new therapies. A few clinical assessments, along with structural and functional neuroimaging, have been utilized in the last few years with some success in this area. Additionally, a number of other strategies have been employed to identify biochemical/molecular biomarkers associated with cognitive impairment and dementia in PD, e.g., targeted analysis of candidate proteins known to be important to PD pathogenesis and progression in cerebrospinal fluid or blood. Finally, interesting results are emerging from preliminary studies with unbiased and high throughput genomic, proteomic and metabolomic techniques. The current findings and perspectives of applying these strategies and techniques are reviewed in this article, together with potential areas of advancement.

Keywords: Parkinson disease, dementia, mild cognitive impairment, biomarker, cerebrospinal fluid, proteomics, genomics, and metabolomics


Parkinson disease (PD), the second most common neurodegenerative disease after Alzheimer disease (AD), has been recently recognized as a disease that encompasses more than just nigrostriatal degeneration with motor dysfunction (43, 74). More specifically, a significant portion of PD patients suffer from non-motor symptoms, including anosmia, constipation, depression, autonomic failure, and cognitive dysfunction. There is growing evidence that cognitive symptoms are frequently present at the time of diagnosis (40), contribute heavily to disability (144), and progress to dementia at a rapid rate. PD with dementia (PD-D) shares a common neuropathological pattern, cognitive profile, and clinical course with a closely related condition, dementia with Lewy-bodies (DLB). The pathological hallmark of both PD-D and DLB is the presence of Lewy bodies — ubiquitin-positive and α-synuclein (α-Syn)-enriched intracytoplasmic neuronal inclusions — in neocortical and paralimbic regions, which seems to be one of the main pathological correlates of dementia in PD (3, 9). The cognitive profile of PD-D (and DLB for that matter) also overlaps partially with that of AD, the most common form of geriatric dementia, and AD-type pathology (such as neurofibrillary tangles and amyloid plaques) frequently co-exists with Lewy body pathology, making correct diagnosis of PD-D difficult even in the best hands. The sensitivity and specificity of the recently published PD-D diagnostic criteria (35, 38) have not yet been explored, but, as expected, the diagnosis will be challenging when patients fall in between the two classic profiles of DLB and PD-D (77). Even for clinical DLB, most studies based on the consensus criteria for clinical diagnosis of DLB (89, 90) have reported a high specificity (80–100%) but a low sensitivity (20–60%) (87), meaning that the consensus criteria are appropriate for confirmation of diagnosis but are of limited value in screening for DLB. In addition, distinguishing the Lewy body disorders from non-Lewy body dementias, including AD, remains difficult when atypical presentations occur during or at early stages of the diseases (78, 79, 88).

As such, identifying individuals who are predisposed to developing cognitive impairment and dementia in PD and other neurodegenerative disorders at early stages of disease progression will allow physicians to better assess the individual's prognosis and make informed decisions on the best course of management (141). In addition, potential neuroprotective or neurorestorative therapies and secondary prevention efforts might be expected to have their greatest impact during the earliest phases of the disease process. Therefore, during the development and implementation of neuroprotective therapies, it will be important to develop robust biomarkers - whether based on clinical assessment, structural/functional imaging, or biochemical measurement in body fluids - that can aid in specific and accurate diagnosis, particularly at early disease stages, and can objectively monitor progression and response to treatment. Biochemical/molecular markers, particularly, could also potentially reveal mechanisms involved in disease pathogenesis and thereby provide new targets for therapy.

Biomarkers for Cognitive Impairment in PD

Significant effort has been spent in several areas to define biomarkers for cognitive impairment in PD, including physiological/sensory testing, structural/functional neuroimaging, and biochemical determination of various molecules. Table 1 lists advantages, disadvantages, and the current status of the major techniques employed for PD-D and DLB biomarker discovery. Of note, the applications of structural and functional neuroimaging and electrophysiological techniques on the diagnosis of PD-D and DLB have already been extensively discussed previously (1, 6, 43, 112, 129).

Table 1
Techniques for PD-D and DLB biomarker discovery

Electrophysiological and sensory markers

Differences exist in the electrophysiological profiles of different types of dementia, both in the amount of slowing as well as the distribution of electrophysiological changes. Several electrophysiological studies have shown more slowing of electroencephalographic (EEG) rhythm in DLB than in AD (2). A recent study has shown that patients with DLB and PD-D have more posterior slow-frequency variation than patients with AD and healthy controls (18). Similarly, another study, which assessed mismatch negativity (MMN) of the auditory event-related potential (ERP), concluded that reduced latency and areas were found in PD-D, compared with AD, PD without dementia (PD-ND) patients, and healthy controls; furthermore, more pronounced changes were found in PD-D than those observed in DLB (22). Studies also reported that PD-D patients had distinctly slower baseline EEG activity than PD-ND patients (43), and that a positive correlation occurred between EEG frequency and cognitive scores (126). Although these results indicate that EEG and ERP may provide a potential diagnostic marker to distinguish between Lewy body disease (including PD-D and DLB) and other dementia diseases, most of these studies were based on small numbers of patients and provided no evidence indicating sensitivity and specificity values.

Additionally, olfactory dysfunction has been identified in PD-D and DLB (55, 117); but this observation is nonspecific because patients with AD have similar olfactory deficits. It could be that the main utility of olfactory testing may be to differentiate neurodegenerative diseases from non-neurodegenerative dementia, such as multi-infarct state, that have no impairment of olfaction (45).

Structural an functional neuroimaging markers

Neuroimaging studies using structural magnetic resonance imaging (MRI) have demonstrated that PD-D is associated with cortical atrophy and that the pattern of atrophy differs from that of AD (24), with significant differences between PD-D and PD-ND reported bilaterally in the occipital lobes. Greater whole-brain atrophy rates were observed in PD-D patients than in PD-ND patients and healthy control subjects (23). Regional changes in key areas such as caudate (7), hippocampus (25), and amygdalae (69) were also reported to be associated with PD-D. Notably, atrophy of the amygdalae and the head of hippocampus were reported recently in PD patients without dementia, indicating early memory impairment (20, 68). Similarly, two recent studies (12, 92) have reported areas of brain atrophy in PD with mild cognitive impairment (MCI) for early changes. Still, there is considerable overlap of regional patterns of atrophy that occur between PD-D and PD-ND and between PD-D and DLB (25, 69). Moreover, sample sizes have not been large enough in most studies to allow for statistical modeling to control for the increased motor impairment and longer disease duration often seen in PD-D compared with PD-ND patients (38, 43).

Functional neuroimaging modalities, including positron emission tomography (PET), single photon emission computer tomography (SPECT), and functional MRI (fMRI), provide valuable information on brain function in the neuropsychiatric aspects of PD. A characteristic posterior perfusion deficit or decreased cerebral blood flow has been shown by SPECT in PD-D as well as DLB (8), but whether this observation is sufficiently distinctive for PD-D and clinically useful for diagnostic purposes remains to be investigated (38, 43). fMRI has also been used to identify brain changes associated with visual hallucinations in PD (132), and the use of 18F-fluorodeoxyglucose (FDG) PET to study non-demented PD patients while they were performing executive and memory tasks, has identified a metabolic pattern (60). It has appeared that changes in this network could distinguish PD with and without MCI (59), and more importantly, changes in this network with time (i.e. progression) were identified (61).

Both PET studies using 18F-fluorodopa and SPECT studies using a range of ligands that bind to the dopamine transporter (DAT) have been shown to identify dopaminergic deficits in PD (45). A growing body of literature shows that these same dopaminergic deficits can be found in PD-D or DLB and that these imaging modalities may be used to differentiate Lewy body disorders from AD. 18F-dopa uptake in PD-D has been reported to be significantly decreased in several areas compared with PD (64); however, in other studies, no differences in dopaminergic loss and rate of dopamine decline were found in PD-D and PD-ND patients (32, 115). Also, functional imaging of the cholinergic system has shown substantial cholinergic denervation in PD-D patients as compared with PD-ND patients (17, 57), although differences were not always significant (17).

In PET studies, 11C-Pittsburgh Compound B (PIB) binds to amyloid with a pattern similar to the histopathologically known distribution in AD. Elevated PIB-binding in the brain stem of PD was recently reported, and in a subgroup, cortical PIB binding was indeed found (81, 82), indicating that PIB-PET could be used to further differentiate PD-D with respect to cortical amyloid.

Finally, though currently preliminary, a few novel functional neuroimaging based biomarkers for PD-D have been investigated. For instance, lactate/N-acetyl aspartate ratio was found to be increased in the occipital lobes in PD, particularly in PD-D patients as compared to healthy controls, suggesting that the impairment of oxidative energy metabolism is greater in PD-D (21, 38). Additionally, using proton magnetic resonance spectroscopy, N-acetyl aspartate was found to be decreased in the occipital lobes in PD-D patients as compared to healthy control or PD-ND subjects (134). Also, the uptake of cardiac metaiodobenzylguanidine (MIBG), a specific marker for noradrenergic transporters, is significantly reduced in PD (135, 147) as well as in DLB (105). Although specific studies in PD-D are lacking, MIBG has been found to be more accurate than occipital hypoperfusion using SPECT (51) or CSF markers (140) as a means of discriminating between DLB and AD. Cardiac MIBG may differentiate Lewy body-related dementias from non-Lewy body related types, but cannot differentiate PD-D and DLB.

Taken together, group differences between PD-D/DLB and PD-ND patients have been documented in electrophysiological/sensory studies as well as structural and functional imaging investigations; however, none of these techniques can be recommended for current routine diagnostic purposes because of inadequate sensitivity or specificity, or relatively high expenses (43). Consequently, additional biomarkers with higher sensitivity and specificity, which can also be applied widely and at a reasonable cost, are needed for greater accuracy and diagnostic utility, ideally at preclinical or early stages of disease when therapy is likely to have the greatest impact.

Biochemical and molecular biomarkers

Genetic markers

Familial aggregation of PD-D and an increased frequency of dementia in the relatives of PD or PD-D patients have been reported in some studies (73, 85), probably reflecting an influence of genetic factors in the development of dementia in PD. The precise role of genetic factors in development of MCI and dementia in PD is unclear currently, though a few candidate genes have been implicated.

  1. Apolipoprotein E (APOE): The e4 allele is associated with a higher risk and earlier onset of AD (86), and an association between APOE genotype and PD-D or DLB has been hypothesized. A few studies have reported that the e2 or e4 allele was associated with a higher prevalence of dementia in PD (34, 53, 62). However, the e4 association was not confirmed in a number of other studies, particularly when PD-D was defined using more strict criteria (38, 43, 65). An alternative explanation could be that the patient populations are different in these varying studies, with the positive ones being associated with PD-D superimposed by Alzheimer's type changes.
  2. Microtubule associated protein (MAP): The H1 haplotype of the MAP gene, encoding tau protein, has been reported to be over-represented in PD, and the cognitive decline and development of PD dementia has been strongly associated (p = 10-4) with the H1/H1 haplotype (47).
  3. α-Syn and leucine-rich repeat kinase 2 (LRRK2): Dementia has also been reported in familial forms of PD such as PARK1 (SNCA) and PARK8 (LRRK2) (38). A relationship between α-Syn dosage and clinical phenotype, including age of onset, progression, and symptom severity (development of dementia) has been reported (116). Patients displaying various mutations in LRRK2 have shown a low rate of cognitive dysfunction and dementia (54, 56).

Based on these findings, it is clear that genetic testing, at least in its current form, is not a convenient or reliable source of biomarkers for diagnosis of cognitive impairment in PD.

CSF and blood-based markers

Human CSF, being most proximal to the CNS, is one of the ideal sources for identifying biomarkers for neurodegenerative diseases. An important consideration is relative availability of CSF obtained by lumbar puncture, making it possible to conduct longitudinal molecular analyses of changes in CSF during the course of diseases. In addition to CSF, the use of plasma, urine, and saliva for biomarker discovery have also been explored as more practical/acceptable approaches; nevertheless, with only few exceptions these attempts have met with limited success, primarily because of the complexity of peripheral samples and confounding factors introduced by other organ systems (123). It was proposed that the best approach might be to establish an ensemble of effective biomarkers in well-characterized human CSF of a relatively small number of individuals involved in research settings, then subsequently pursue their quantification in plasma or urine/saliva for more wide spread application (148). The biochemical/molecular candidate markers will be reviewed in two categories – targeted analysis and unbiased profiling.

Targeted analysis
  1. Amyloid-β (Aβ), total and phosphrylated tau: It is well established that reduced concentrations of Aβ peptide, combined with increased total and phosphorylated tau, has a reasonable sensitivity and specificity in differentiating patients with AD from older individuals without cognitive impairment and from those with other dementias (28, 50, 121). Concentrations of Aβ1–42 have been reported to be higher in patients with DLB than in aged-matched controls (46), but the majority of sensitivity and specificity studies do not indicate that the levels of CSF Aβ1–40 or Aβ1–42 can usefully discriminate between DLB and AD (2, 137). More recently, a novel peptide, an oxidised α-helical form of Aβ1–40 (Aβ1-40ox), was found to be significantly increased in DLB with a diagnostic sensitivity of 88% and a specificity of 73% (14, 15). DLB patients have been shown to have a specific increase in Aβ1-40ox compared to PD-D patients and nondemented disease controls (14). Differences in total tau (30) and phosphorylated tau (30, 98, 137) appear to be more robust in distinguishing DLB and AD on a group basis, with the sensitivity of discrimination in the 70–80% range, but the large variability renders total tau and phosphorylated tau less useful as potential diagnostic markers for individual patients (2, 97). Fewer studies have been reported in PD-D. Tau-protein levels were found to be higher and Aβ1–42 lower in the patients with PD-D compared with PD-ND patients and normal controls (101). On the other hand, a recent study found no significant differences in CSF Aβ1–42 and total tau levels between patients with PD-D and those with PD-ND (109), though there was still a trend of higher total tau and lower Aβ1–42 levels in PD-D than in PD-ND. A better understanding of the relationship between AD pathology and PD-D disease course is essential if these classical CSF markers of AD are to be of use in differential diagnosis, and studies with larger samples are needed to clarify the role of these biomarkers for cognitive impairment and dementia in PD. Another approach could be to focus on the patients with more amnestic symptoms, because it is possible that cognitive impairment in these subjects is more (than those to be discussed below) related to co-existing AD type changes.
  2. α-Syn: Extracellular forms of α-syn, the key protein in the pathogenesis of PD and DLB, have been identified, including in CSF and plasma (19, 36, 37, 76, 136). Reduced levels of α-syn in the CSF have been associated with increasing severity of parkinsonism in patients with PD (136). A recent study (99) demonstrated that soluble α-syn was reduced in patients with advanced PD and DLB compared with AD and non-neurodegenerative disease controls. A reduced α-syn level in PD/DLB patients has been proposed to be a consequence of deposition of α-syn in the CNS. However, a reduced α-syn level in PD/DLB in CSF was not confirmed in some other investigations (103, 104, 131). Studies on α-syn in peripheral plasma have also shown inconsistent results. Lee et al (75) has reported increased plasma α-syn levels in PD and multiple system atrophy (MSA) compared to aged-matched healthy controls by a commercially available ELISA kit, while Li et al (76) has reported decreased plasma α-syn levels in PD compared to normal controls measured by Western blotting. The discrepancy could be due to additionally quantified oligomers and other cross-reactive molecules by the ELISA technique (76) or the limitation of the ELISA kit (the kit was reported to measure α-syn in a range above the reported level) (39). Interestingly, preliminary findings have also shown a significant increase in α-syn oligomers in plasma in patients with PD compared with controls (37). There are still no direct assessments of α-syn in plasma from PD-D and DLB patients.
  3. DJ-1: DJ-1, another protein important in both familial and sporadic PD and believed to be related to oxidative stress (52), has also been identified in CSF and plasma (83, 142, 143). One study using Western blotting has reported that CSF DJ-1 levels in PD, particularly early stages of PD, were higher than those in non-PD controls (143). The plasma DJ-1 levels measured by Western blotting and ELISA were also increased in PD and DLB compared with controls, and correlated with the disease severity in PD (142). However, another study has shown no significant difference between the serum DJ-1 levels in PD patients and healthy controls (83).
  4. Heart-type fatty acid-binding protein (H-FABP): H-FABP was initially identified as a potential CSF biomarker for Creutzfeldt-Jakob disease (CJD) by 2-dimensional (2D) gel electrophoresis (48). It was later shown to be also increased in the serum, but not CSF, of DLB patients (133). In a further study, determination of the H-FABP concentration by means of an ELISA analysis of serum could differentiate DLB from PD with high sensitivity and specificity (100). In addition, PD could be distinguished from PD-D with a sensitivity of 69% and a specificity of 80%. PD-D could also be differentiated from healthy subjects with a sensitivity of 92% and a specificity of 64%. By determining the quotient of serum H-FABP/CSF tau protein, PD-D could be differentiated from AD with a sensitivity of 88% and a specificity of 74%. Yet, PD-D could not be differentiated from DLB within the context of this study. Another group confirmed the increased levels of H-FABP in DLB and PD patients compared to AD, but the diagnostic value (sensitivity 47%, specificity 91%) of serum H-FABP for DLB was inferior to that of the H/M ratio determined by 123I-MIBG cardiac scintigraphy (139). Significant positive correlation of serum H-FABP levels with the severity of PD (Hohen–Yahr stage) was also shown in this study.

Other candidate molecular/biochemical markers include hypocretin, a protein related to the regulation of sleep and wakefulness (94, 146), tissue transglutaminase (138) and serpins (102) that might be associated with aggregation of α-syn, homocysteine (63), neurotransmitter metabolites such as homovanillic acid (HVA) and methoxy-hydroxy-phenyl-ethylene glycol (MHPG) (5, 27, 108), growth hormone in serum (31, 70, 110, 111, 118), osteopontin (80), amino acids relevant for synthesis of nitrogen monoxide (72, 84, 95), and metals such as iron and zinc (41, 42, 66, 114). Unfortunately, studies involving these candidate markers are either contradictory or very preliminary, and thus still difficult to interpret.

In summation, though the emerging body of work on the CSF and blood biomarkers of PD is encouraging (a list of recent findings, along with the associated references, is summarized in Table 2), one of the issues that has plagued the field is a lack of reproducibility between researchers. The disparity can be attributed to several factors, including variation in antibodies that might detect different species of the target protein, limited numbers of patients in some investigations, a less than vigorous quantitative method, or inadequate control for important confounding factors, particularly blood contamination in CSF (148). Further studies are needed to clarify these issues, ideally in CSF and blood samples with pathological verification of clinical diagnosis of each case.

Table 2
Potential cerebrospinal fluid (CSF) and blood biomarkers for PD and PD-D

Unbiased discovery

While targeted analysis of biomarkers as discussed above is largely an extension of physiological studies that investigate known pathways involved in PD pathogenesis, emerging technologies are beginning to allow a systematic, unbiased characterization of variation in genes, messenger RNA (mRNA), proteins and metabolites associated with disease conditions and identification of novel biomarkers (49, 120, 123).

  1. Microarray: Genomic technologies such as microarray enable the simultaneous interrogation of the expression level of thousands of genes to obtain a quantitative assessment of their differential activity in a given tissue or cell. The development of these technologies has also motivated interest of their use in clinical trials and diagnosis. Many studies have attempted to find subsets of genes that distinguish well between samples from different groups such as disease and controls. In a recent study, a set of gene markers were identified and validated in blood to indicate early PD (119). This suggests that gene/RNA expression signals that can be measured in routinely collected blood samples could facilitate the development of biomarkers for PD and potentially PD-D or DLB. It remains to be investigated, however, whether the altered genes are uniquely associated with those produced in the CNS or are just surrogate markers of PD.
  2. Metabolomics: Metabolomic profiling is the quantitative measurement of a large number of low molecular weight molecules (metabolites) within a particular sample type (113). It captures the status of diverse biochemical pathways at a particular moment and defines a metabolic state such as health or disease state. The comprehensive study of the metabolome could lead to the identification of new disease-specific signature(s) as possible biomarkers. A metabolomic biomarker that predicts disease, measures progression, or monitors therapy could potentially be a single molecule or a pattern of several molecules. Using metabolomic technologies, several recent preliminary studies (16, 93) have identified metabolomic signatures in plasma/serum and urine in PD which appear to separate PD patients from controls. However, it is important to investigate whether these metabolomic changes are specifically related to PD, since metabolites of blood and/or urine are not only liable to ex vivo alterations but are also potentially influenced by many other organ systems.
  3. Proteomics: Proteomics is the study of both the structure and function of proteins by a variety of methods. Advancing technologies, particularly the evolution of 2D gel electrophoresis-based approaches into liquid chromatography (LC)-based high-resolution tandem mass spectrometry (MS/MS), have radically improved the speed and precision of identifying and measuring proteins in biological fluids and other samples. The emerging technology of quantitative proteomics also provides a unique opportunity to reveal static or perturbation-induced changes in a protein profile. Indeed, compared to genomics and metabolomics, proteomics perhaps has garnered more recent attention, largely because proteins are readily available in body fluids (a particularly important point in diseases of the CNS) and are more stable than mRNA and metabolites. However, due to the enormous complexity of biological systems and the complex nature of proteins, an effective, unbiased proteomics profiling (protein profiling without any type of pre-selection for biomarkers) requires a multi-discipline approach to accomplish the goal of protein identification and quantification. Such a concerted approach typically includes several components, including sample preparation, protein or peptide separation, protein or peptide identification by MS or MS/MS and bioinformatics data processing, as well as independent confirmation and validation (123) (Fig. 1).
    Fig. 1
    Work flow of typical quantitative proteomic experiments for biomarker discovery

Over the last few years, proteomic techniques have been utilized to discover novel markers in different neurodegenerative disease settings, with AD being studied most extensively (33, 121, 123, 130). On the other hand, it has also become clear that the proteomics results reported by different groups vary substantially. Some of these variations may be biological, as human beings are extremely heterogeneous, and most diseases studied are very complex. To resolve this issue, multiple markers may be needed, as a combination of independent markers likely enhances the performance of the putative markers required (4, 29, 125). In addition, standardization of data reported is also critical to reducing inconsistency among different studies. It is almost certain that the differences in databases has contributed to the current inconsistent (and often contradicting) results in CSF biomarker discovery (148). As one of the initiatives to address this issue, we have recently summarized and standardized all of our CSF proteomics results, as well as made the original MS data available to investigators in the field (107) so that future discoveries can be compared to the published results meaningfully.

In proteomic studies for PD biomarker discovery in CSF, one recent study employed an unbiased quantitative proteomic approach called isobaric tagging for relative and absolute protein quantification (iTRAQ) to label human CSF from AD, PD, and DLB patients and healthy controls, and identified more than 1500 proteins; of those, 136, 72, and 101 proteins appeared to be uniquely associated with AD, PD, and DLB, respectively (4). Some of the unique proteins, including apolipoprotein H/beta-2-glycoprotein 1 (Apo-H), ceruloplasmin and chromogranin B (secretogranin I) that are unique to PD as well as apoC1 and T-cadherin that are unique to DLB, were further confirmed in the initial study using Western blotting. Additionally, the ability to distinguish DLB from PD and AD increased when several markers were combined. Besides the proteins confirmed in this initial investigation, several other markers have been tested in a different and larger set of subjects, in which a panel of eight CSF proteins (BDNF, IL-8, VDBP, β2-microglobulin, apoAII, apoE, plus tau and Aβ1-42) appears to be able to classify PD patients with 95% sensitivity and 95% specificity using bead-based Luminex multi-analyte profiling technology (149). Whether these markers are useful in detecting PD-D/DLB remain to be investigated.

It cannot be stressed enough that biomarker discovery does not have to start with body fluids. This is because protein biomarkers identified in human brain may also ultimately enter CSF and/or plasma that can be collected clinically in a living patient. These brain specific markers are difficult to identify in unbiased direct profiling of CSF because they are typically low in abundance, and all current proteomics technology is biased towards abundant proteins. Thus, defining proteins in well-characterized brain tissue, followed by targeted validation of candidate proteins in the CSF and blood is indeed an approach currently taken for PD and DLB biomarker discovery. In this regard, several tissue-based proteomics studies have identified many differentially expressed proteins in PD tissues with respect to controls (11, 67, 71, 106, 122, 124, 145). Some of the proteins, including mortalin (124) and glutathione S-transferase pi (122), were also identified to display significant differences between different PD stages. A subset of these proteins is under intensive investigation as to their contribution to PD development and progression. The deregulated proteins in PD tissue are also being interrogated as potential biomarkers in body fluids, including CSF and plasma.

Concluding Comments and Future Directions

The advantages of early diagnosis, combined with suboptimal clinical diagnostic accuracy, highlight the need for a valid biological marker(s) for PD with MCI and PD-D. Promising results have been reported from several neuroimaging and hypothesis-driven targeted analysis of proteins in CSF and blood. Unbiased discovery based on genomics, metabolomics, and proteomics has also yielded hopeful results. It is expected that future studies using these strategies will provide novel, more accurate, and less expensive biomarkers and explore whether a combination of different biomarkers can improve diagnostic accuracy. Another potential fruitful area in discovery of biomarkers for cognitive impairment might be the research on post-translational modifications (PTMs) of proteins, e.g. phosphorylation, ubiquitination, and glycosylation, as aberrant PTMs of proteins have now been recognized as an attribute of many mammalian diseases, including neurodegenerative diseases (10, 44, 91). To this end, phosphorylated and/or glycosylated α-syn have been clearly linked to PD pathogenesis, and it is possible that it is the modified α-syn, rather than the total level of α-syn, that reflects disease activity and prognosis. More detailed discussions of the current technologies being utilized as well as potential shortcomings and limitations of the analysis of PTMs as biomarkers of neurodegenerative disease can be found in recently published reviews (26, 148).

Finally, for future investigations, it is critical to address several important issues, including standardization of sample collection protocols, the specificity of the antibodies and the technologies used, and the need to recruit a larger number of subjects and controls, allowing for stratification against important variables typically associated with clinical investigations. These variables have likely contributed to inconsistent results, whether via targeted or unbiased profiling, obtained thus far by various investigators. Independent studies on different cohorts, including cases with pathological verification, are also needed for validation.


This work was supported by grants from the NIH (NS057567, NS060252, ES004696, AG033398, AG025327, and NS062684) and the C-M Shaw Endowment.


1. Aarsland D, Beyer MK, Kurz MW. Dementia in Parkinson's disease. Curr Opin Neurol. 2008;21(6):676–82. [PubMed]
2. Aarsland D, Kurz M, Beyer M, Bronnick K, Piepenstock Nore S, Ballard C. Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. Dement Geriatr Cogn Disord. 2008;25(3):195–205. [PubMed]
3. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol. 2005;58(5):773–6. [PubMed]
4. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9(3):293–348. [PubMed]
5. Abdo WF, De Jong D, Hendriks JC, Horstink MW, Kremer BP, Bloem BR, Verbeek MM. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Mov Disord. 2004;19(5):571–9. [PubMed]
6. Adamis D, Sahu S, Treloar A. The utility of EEG in dementia: a clinical perspective. Int J Geriatr Psychiatry. 2005;20(11):1038–45. [PubMed]
7. Almeida OP, Burton EJ, McKeith I, Gholkar A, Burn D, O'Brien JT. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord. 2003;16(2):57–63. [PubMed]
8. Antonini A, De Notaris R, Benti R, De Gaspari D, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci. 2001;22(1):45–6. [PubMed]
9. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, Perry E, Aarsland D. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67(11):1931–4. [PubMed]
10. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8(9):663–72. [PubMed]
11. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics. 2004;4(12):3943–52. [PubMed]
12. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry. 2007;78(3):254–9. [PMC free article] [PubMed]
13. Bibl M, Esselmann H, Mollenhauer B, Weniger G, Welge V, Liess M, Lewczuk P, Otto M, Schulz JB, Trenkwalder C, Kornhuber J, Wiltfang J. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem. 2007;103(2):467–74. [PubMed]
14. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Ruther E, Kornhuber J, Otto M, Wiltfang J. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain. 2006;129(Pt 5):1177–87. [PubMed]
15. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, Otto M, Stiens G, Ruther E, Kornhuber J, Wiltfang J. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry. 2007;12(7):671–80. [PubMed]
16. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain. 2008;131(Pt 2):389–96. [PubMed]
17. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis Ch A, Davis JG, Moore RY, Dekosky ST. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol. 2006;253(2):242–7. [PubMed]
18. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690–705. [PubMed]
19. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, Abbruzzese G, Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett. 2000;287(1):65–7. [PubMed]
20. Bouchard TP, Malykhin N, Martin WR, Hanstock CC, Emery DJ, Fisher NJ, Camicioli RM. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging. 2008;29(7):1027–39. [PubMed]
21. Bowen BC, Block RE, Sanchez-Ramos J, Pattany PM, Lampman DA, Murdoch JB, Quencer RM. Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. AJNR Am J Neuroradiol. 1995;16(1):61–8. [PubMed]
22. Bronnick KS, Nordby H, Larsen JP, Aarsland D. Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study. Neurobiol Aging 2008 [PubMed]
23. Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord. 2005;20(12):1571–6. [PubMed]
24. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain. 2004;127(Pt 4):791–800. [PubMed]
25. Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson's disease is associated with hippocampal atrophy. Mov Disord. 2003;18(7):784–90. [PubMed]
26. Caudle WM, Pan S, Shi M, Quinn T, Hoekstra J, Beyer RP, Montine TJ, Zhang J. Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. Proteomics Clin Appl. 2008;2(10-11):1484–97. [PMC free article] [PubMed]
27. Chia LG, Cheng LJ, Chuo LJ, Cheng FC, Cu JS. Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. J Neurol Sci. 1995;133(1-2):73–8. [PubMed]
28. Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee VM, Trojanowski JQ. Biomarkers for early detection of Alzheimer pathology. Neurosignals. 2008;16(1):11–8. [PMC free article] [PubMed]
29. Clark CM, Pratico D, Shaw LM, Leight S, Xie SX, Gu A, Lee VMY, Trojanowski JQ. Biochemical biomarkers of late-life dementia. Alzheimers Dement. 2006;2(4):287–93. [PMC free article] [PubMed]
30. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW, Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60(12):1696–702. [PubMed]
31. Clarke CE, Ray PS, Speller JM. Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease. Lancet. 1999;353(9161):1329–30. [PubMed]
32. Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging. 2005;32(10):1176–85. [PubMed]
33. de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM. Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin Chem Lab Med. 2007;45(11):1421–34. [PubMed]
34. de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62(8):1265–9. [PubMed]
35. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314–24. [PubMed]
36. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, Cookson MR, Hardy J, Allsop D. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003;17(13):1945–7. [PubMed]
37. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006;20(3):419–25. [PubMed]
38. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007;22(12):1689–707. quiz 837. [PubMed]
39. Fjorback AW, Varming K, Jensen PH. Determination of alpha-synuclein concentration in human plasma using ELISA. Scand J Clin Lab Invest. 2007;67(4):431–5. [PubMed]
40. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain. 2004;127(Pt 3):550–60. [PubMed]
41. Forte G, Alimonti A, Pino A, Stanzione P, Brescianini S, Brusa L, Sancesario G, Violante N, Bocca B. Metals and oxidative stress in patients with Parkinson's disease. Ann Ist Super Sanita. 2005;41(2):189–95. [PubMed]
42. Forte G, Bocca B, Senofonte O, Petrucci F, Brusa L, Stanzione P, Zannino S, Violante N, Alimonti A, Sancesario G. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm. 2004;111(8):1031–40. [PubMed]
43. Goetz CG, Emre M, Dubois B. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008;64 2:S81–92. [PubMed]
44. Golab J, Bauer TM, Daniel V, Naujokat C. Role of the ubiquitin-proteasome pathway in the diagnosis of human diseases. Clin Chim Acta. 2004;340(1-2):27–40. [PubMed]
45. Goldmann Gross R, Siderowf A, Hurtig HI. Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease. Neurosignals. 2008;16(1):24–34. [PubMed]
46. Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, Yebenes JG, del Ser T. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol. 2003;60(9):1218–22. [PubMed]
47. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol. 2007;62(2):145–53. [PubMed]
48. Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics. 2003;3(8):1495–9. [PubMed]
49. Han X. An update on lipidomics: progress and application in biomarker and drug development. Curr Opin Mol Ther. 2007;9(6):586–91. [PubMed]
50. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–34. [PubMed]
51. Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, Usui Y, Yamashina A, Koizumi K, Abe K. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2006;33(3):248–53. [PubMed]
52. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C. The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev. 2009;19(3):254–65. [PubMed]
53. Harhangi BS, de Rijk MC, van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology. 2000;54(6):1272–6. [PubMed]
54. Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008;70(16 Pt 2):1456–60. [PMC free article] [PubMed]
55. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord. 2003;18(4):364–72. [PubMed]
56. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008;7(7):583–90. [PMC free article] [PubMed]
57. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65(11):1716–22. [PubMed]
58. Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 2003;18(2):186–90. [PubMed]
59. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008;70(16 Pt 2):1470–7. [PubMed]
60. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage. 2007;34(2):714–23. [PubMed]
61. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Changes in network activity with the progression of Parkinson's disease. Brain. 2007;130(Pt 7):1834–46. [PubMed]
62. Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol. 2006;63(2):189–93. [PubMed]
63. Isobe C, Murata T, Sato C, Terayama Y. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci. 2005;77(15):1836–43. [PubMed]
64. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, Hatano K, Abe Y, Yamada T, Kachi T, Brooks DJ. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain. 2002;125(Pt 6):1358–65. [PubMed]
65. Jasinska-Myga B, Opala G, Goetz CG, Tustanowski J, Ochudlo S, Gorzkowska A, Tyrpa J. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007;64(2):261–5. [PubMed]
66. Jimenez-Jimenez FJ, Molina JA, Aguilar MV, Meseguer I, Mateos-Vega CJ, Gonzalez-Munoz MJ, de Bustos F, Martinez-Salio A, Orti-Pareja M, Zurdo M, Martinez-Para MC. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J Neural Transm. 1998;105(4-5):497–505. [PubMed]
67. Jin J, Hulette C, Wang Y, Zhang T, Pan C, Wadhwa R, Zhang J. Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics. 2006;5(7):1193–204. [PubMed]
68. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord. 2009;15(2):88–93. [PubMed]
69. Junque C, Ramirez-Ruiz B, Tolosa E, Summerfield C, Marti MJ, Pastor P, Gomez-Anson B, Mercader JM. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord. 2005;20(5):540–4. [PubMed]
70. Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet. 1997;349(9069):1877–81. [PubMed]
71. Kitsou E, Pan S, Zhang J, Shi M, Zabeti A, Dickson DW, Albin R, Gearing M, Kashima DT, Wang Y, Beyer RP, Zhou Y, Pan C, Caudle WM, Zhang J. Identification of proteins in human substantia nigra. Proteomics Clin Appl. 2008;2(5):776–82. [PubMed]
72. Kuiper MA, Teerlink T, Visser JJ, Bergmans PL, Scheltens P, Wolters EC. L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm. 2000;107(2):183–9. [PubMed]
73. Kurz MW, Larsen JP, Kvaloy JT, Aarsland D. Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study. Mov Disord. 2006;21(12):2170–4. [PubMed]
74. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med. 1998;339(15):1044–53. [PubMed]
75. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm. 2006;113(10):1435–9. [PubMed]
76. Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, Masters CL, Culvenor JG, Horne MK. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol. 2007;204(2):583–8. [PubMed]
77. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68(11):812–9. [PubMed]
78. Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D'Olhaberriague L, Pearce RK, Agid Y. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55(7):969–78. [PubMed]
79. Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, Becker JT, DeKosky ST. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology. 1999;53(6):1292–9. [PubMed]
80. Maetzler W, Berg D, Schalamberidze N, Melms A, Schott K, Mueller JC, Liaw L, Gasser T, Nitsch C. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol Dis. 2007;25(3):473–82. [PubMed]
81. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34(1):107–12. [PubMed]
82. Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, Eschweiler GW, Mittelbronn M, Gaenslen A, Uebele M, Reischl G, Gasser T, Machulla HJ, Bares R, Berg D. [11C]PIB binding in Parkinson's disease dementia. Neuroimage. 2008;39(3):1027–33. [PubMed]
83. Maita C, Tsuji S, Yabe I, Hamada S, Ogata A, Maita H, Iguchi-Ariga SM, Sasaki H, Ariga H. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett. 2008;431(1):86–9. [PubMed]
84. Mally J, Szalai G, Stone TW. Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J Neurol Sci. 1997;151(2):159–62. [PubMed]
85. Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Louis E, Stern Y, Mayeux R. Risk of Alzheimer's disease in relatives of Parkinson's disease patients with and without dementia. Neurology. 1999;52(4):719–24. [PubMed]
86. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998;338(8):506–11. [PubMed]
87. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien J, Playfer J, Reid W. Dementia with Lewy bodies. Lancet Neurol. 2004;3(1):19–28. [PubMed]
88. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A, Fairbairn AF, Perry EK. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54(5):1050–8. [PubMed]
89. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72. [PubMed]
90. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–24. [PubMed]
91. Mechref Y, Madera M, Novotny MV. Glycoprotein enrichment through lectin affinity techniques. Methods Mol Biol. 2008;424:373–96. [PubMed]
92. Meyer JS, Huang J, Chowdhury MH. MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. J Neurol Sci. 2007;257(1-2):97–104. [PubMed]
93. Michell AW, Mosedale D, Grainger DJ, Barker RA. Metabolomic analysis of urine and serum in Parkinson's disease. Metabolomics. 2008;4(3):191–201.
94. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553–62. [PubMed]
95. Molina JA, Jimenez-Jimenez FJ, Gomez P, Vargas C, Navarro JA, Orti-Pareja M, Gasalla T, Benito-Leon J, Bermejo F, Arenas J. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J Neurol Sci. 1997;150(2):123–7. [PubMed]
96. Mollenhauer B, Bibl M, Esselmann H, Steinacker P, Trenkwalder C, Wiltfang J, Otto M. Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm. 2007;114(7):919–27. [PubMed]
97. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielczyk B, Neubert K, Trenkwalder C, Otto M. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med. 2006;44(2):192–5. [PubMed]
98. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2005;19(2-3):164–70. [PubMed]
99. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008;213(2):315–25. [PubMed]
100. Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis. 2007;4(5):366–75. [PubMed]
101. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, Schindehuette J, Poser S, Wiltfang J, Otto M. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2006;22(3):200–8. [PubMed]
102. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, Crowther DC, Lomas DA, Janciauskiene SM. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology. 2007;69(16):1569–79. [PubMed]
103. Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M, El-Agnaf OM, Yamada M. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res. 2009;1251:1–6. [PubMed]
104. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett. 2009;450(3):332–5. [PubMed]
105. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, Tsuchiya K, Mori F, Wakabayashi K, Takahashi H. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 2005;109(6):583–8. [PubMed]
106. Pan S, Shi M, Jin J, Albin RL, Lieberman A, Gearing M, Lin B, Pan C, Yan X, Kashima DT, Zhang J. Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer. Mol Cell Proteomics. 2007;6(10):1818–23. [PubMed]
107. Pan S, Zhu D, Quinn JF, Peskind ER, Montine TJ, Lin B, Goodlett DR, Taylor G, Eng J, Zhang J. A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics. 2007;7(3):469–73. [PubMed]
108. Parkinson-Study-Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol. 1995;52(3):237–45. [PubMed]
109. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry. 2008;64(10):850–5. [PubMed]
110. Pellecchia MT, Longo K, Manfredi M, Lucetti C, Cossu G, Petrone A, Marconi R, Sensi M, Epifanio A, Eleopra R, Marchese R, Scaravilli T, Morgante L, Abbruzzese G, Bonuccelli U, Donati E, Pivonello R, Colao A, Barone P. The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. Mov Disord. 2008;23(2):190–4. [PubMed]
111. Pellecchia MT, Pivonello R, Colao A, Barone P. Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease. Clin Med Res. 2006;4(4):322–5. [PubMed]
112. Piccini P, Brooks DJ. New developments of brain imaging for Parkinson's disease and related disorders. Mov Disord. 2006;21(12):2035–41. [PubMed]
113. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 2009;35(2):165–76. [PubMed]
114. Qureshi GA, Qureshi AA, Memon SA, Parvez SH. Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy. J Neural Transm Suppl. 2006;(71):229–36. [PubMed]
115. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol. 2000;57(4):470–5. [PubMed]
116. Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008;63(6):743–50. [PMC free article] [PubMed]
117. Sakuma K, Nakashima K, Takahashi K. Olfactory evoked potentials in Parkinson's disease, Alzheimer's disease and anosmic patients. Psychiatry Clin Neurosci. 1996;50(1):35–40. [PubMed]
118. Schaefer S, Vogt T, Nowak T, Kann PH. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy. J Neuroendocrinol. 2008;20(1):104–9. [PubMed]
119. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007;104(3):955–60. [PubMed]
120. Sharp FR, Xu H, Lit L, Walker W, Apperson M, Gilbert DL, Glauser TA, Wong B, Hershey A, Liu DZ, Pinter J, Zhan X, Liu X, Ran R. The future of genomic profiling of neurological diseases using blood. Arch Neurol. 2006;63(11):1529–36. [PubMed]
121. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007;6(4):295–303. [PubMed]
122. Shi M, Bradner J, Bammler TK, Eaton DL, Zhang J, Ye Z, Wilson AM, Montine TJ, Pan C, Zhang J. Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. Am J Pathol. 2009;175(1):54–65. [PubMed]
123. Shi M, Caudle WM, Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis. 2009;35(2):157–64. [PMC free article] [PubMed]
124. Shi M, Jin J, Wang Y, Beyer RP, Kitsou E, Albin RL, Gearing M, Pan C, Zhang J. Mortalin: a protein associated with progression of Parkinson disease? J Neuropathol Exp Neurol. 2008;67(2):117–24. [PubMed]
125. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging. 2008;29(7):961–8. [PubMed]
126. Sinanovic O, Kapidzic A, Kovacevic L, Hudic J, Smajlovic D. EEG frequency and cognitive dysfunction in patients with Parkinson's disease. Med Arh. 2005;59(5):286–7. [PubMed]
127. Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;70(5):624–30. [PMC free article] [PubMed]
128. Sjogren M, Minthon L, Davidsson P, Granerus AK, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 2000;107(5):563–79. [PubMed]
129. Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V, Barrio JR. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 2008;7(2):161–72. [PMC free article] [PubMed]
130. Sonnen JA, Keene CD, Montine KS, Li G, Peskind ER, Zhang J, Montine TJ. Biomarkers for Alzheimer's disease. Expert Rev Neurother. 2007;7(8):1021–8. [PubMed]
131. Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis. 2009;16(2):363–9. [PubMed]
132. Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, Gabrieli JD. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004;63(8):1409–16. [PubMed]
133. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett. 2004;370(1):36–9. [PubMed]
134. Summerfield C, Gomez-Anson B, Tolosa E, Mercader JM, Marti MJ, Pastor P, Junque C. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol. 2002;59(9):1415–20. [PubMed]
135. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K, Tonami N. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med. 2000;27(5):566–73. [PubMed]
136. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ, Schlossmacher MG, El-Agnaf OM. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun. 2006;349(1):162–6. [PubMed]
137. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Burger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Blaser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006;44(12):1472–80. [PubMed]
138. Vermes I, Steur EN, Jirikowski GF, Haanen C. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov Disord. 2004;19(10):1252–4. [PubMed]
139. Wada-Isoe K, Imamura K, Kitamaya M, Kowa H, Nakashima K. Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci. 2008;266(1-2):20–4. [PubMed]
140. Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci. 2007;260(1-2):33–7. [PubMed]
141. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14(1):e1–26. [PubMed]
142. Waragai M, Nakai M, Wei J, Fujita M, Mizuno H, Ho G, Masliah E, Akatsu H, Yokochi F, Hashimoto M. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett. 2007;425(1):18–22. [PubMed]
143. Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, Akatsu H, Yamada T, Hashimoto M. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun. 2006;345(3):967–72. [PubMed]
144. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004;52(5):784–8. [PubMed]
145. Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci. 2008;6:8. [PMC free article] [PubMed]
146. Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2006;250(1-2):120–3. [PubMed]
147. Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001;71(5):583–8. [PMC free article] [PubMed]
148. Zhang J. Proteomics of human cerebrospinal fluid - the good, the bad, and the ugly. Proteomics Clin Appl. 2007;1(8):805–19. [PubMed]
149. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526–9. [PMC free article] [PubMed]